Extraordinary meeting to approve Ethiopia subsidiary sale and debt conversion

Board & Shareholder Meetings View source PDF Explain this filing

KILITCH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.3%Reaction day

₹198.39

prior close

₹205.99

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%-0.7% vs market

Pharmaceuticals peers, median of 174sector+1.2%-1.6% vs sector

On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250 and 1.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.9

10m

-2.8

15m

-1.4

30m

-1.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.3+0.4-0.7+1.2-1.6

Next day

+6.4+2.1+4.3+3.1+3.3

+12.2+2.2+9.9+4.7+7.5

+5.5pendingpending+4.7+0.8

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 174Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

An extraordinary general meeting on 16 November 2026 will seek approval to convert INR 57 crore of debt in Ethiopia-based Kilitch Estro Biotech into shares, lifting Kilitch Drugs' stake from 67% to 89.17%, and sell the entire holding to HarmeeCare Pharmaceuticals for USD 12.855 million. Proceeds are intended for debt repayment, interest reduction and the Pen facility. Shareholders will also appoint two independent directors for five years.

Likely market impact

Success could add USD 12.855 million and help cut interest costs, but Kilitch loses the subsidiary. Shareholder approval and completion remain risks.